在成年人的有效性和安全性氧酸盐与异常性高睡眠症:一个随机对照试验
Yves Dauvilliers1,2, Sofiene Chenini1, Ophélie Thobois1
1Sleep-Wake Disorders Center, Department of Neurology, Gui-de-Chauliac Hospital University of Montpellier; National Reference Center for Narcolepsy and Rare Hypersomnias, France.
Neurology
|May 13, 2025
概括
在8周内,氧酸盐 (SXB) 显著改善了过度白天嗜睡,并减少了成年人患有异常性高睡眠症 (IH) 的症状严重程度. 安全性调查结果与之前的SXB研究一致.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 临床药理学 临床药理学
背景情况:
- 异常性高睡眠症 (IH) 是一种罕见的中枢疾病,会导致白天过度的嗜睡,长时间的睡眠和睡眠惯性.
- 低氧酸盐是FDA批准的唯一IH治疗方法,但对其有效性的客观数据有限.
- 这项研究旨在评估氧酸盐 (SXB) 在成年IH患者的疗效和安全性.
研究的目的:
- 评估氧酸盐 (SXB) 在减少异常性高睡眠症 (IH) 患者过度白天嗜睡的疗效.
- 评估SXB对IH中清醒和疾病严重程度的客观指标的影响.
- 确定SXB在IH患者群体中的安全性和耐受性概况.
主要方法:
- 一个第三阶段,双盲,安慰剂控制的试验,涉及45名成年参与者与IH.
- 随机分配到SXB或安慰剂中,剂量从每晚4.5g到9g在6周内定位.
- 主要终点:8周后爱普沃思睡眠度量 (ESS) 评分的变化;次要终点包括IHSS和MWT评分以及安全性评估.
主要成果:
- 与安慰剂相比,SXB显示ESS得分在统计学上显著下降 (LS平均差异: -6.86,p < 0.0001).
- 在SXB的IHSS得分 (LS平均差异:-11.61,p < 0.0001) 和MWT延迟 (14.75,p < 0.0001) 中观察到显著的改善.
- 治疗引起的不良事件,包括恶心,头痛和头,在SXB组 (81.8%) 比安慰剂 (26.1%) 更频繁.
结论:
- 氧化酸 (SXB) 在8周后为患有IH的成年人提供了对过度嗜睡,清醒和整体疾病严重性的临床上有意义的改善.
- 在本试验中观察到的SXB的安全性概况与之前的研究结果一致.
- 这项研究提供了I类证据,支持SXB用于治疗异常性高睡眠症.
相关概念视频
Sedatives and Hypnotics Drugs: Miscellaneous Agents
132
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
132
Management of Insomnia
223
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
223
Narcolepsy
82
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
82
CNS Depressants: Barbiturates and Benzodiazepines
183
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
183
Antiepileptic Drugs: Potassium Channel Activators
134
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
134
Sedatives and Hypnotics: Overview
239
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
239


